Most Popular

1
IMF lowers Korea's 2025 growth outlook to 2%
2
Labor Ministry dismisses Hanni harassment case
3
Reality show 'I Live Alone' disciplined for 'glorifying' alcohol consumption
4
North Korean troops fighting alongside Russia, NIS confirms
5
Now is no time to add pressure on businesses: top executives

6
CJ CheilJedang to spur overseas growth with new Hungary, US plants
7
Japan to hold 1st memorial for Korean forced labor victims at Sado mine
8
[Herald Interview] How Gopizza got big in India
9
[KH Explains] Dissecting Hyundai Motor's lobbying in US
10
Nearly half of pines at Seoraksan face extinction due to global warming: study

NewsletterSubscribe

Start your day with a roundup of key stories from The Korea Herald with news and comment on all that’s happening in Korea.

Korea United Pharm’s W38m contract canceled

By 황유미

Published : Oct. 12, 2016 - 17:59

- Link copied

[DISCLOSURE] Korea United Pharm (033270) announced on Oct. 12 that its 38.4 billion won (US$34.18 million) contract with Jiangxi JiminKexin Group to supply its incrementally modified drug Cilostan Tabs has been canceled upon the Chinese company’s request. This amounts to 23.7 percent of the South Korean pharma company’s sales in 2015.

The contract to supply Clanza Tabs will remain in effect.

Cilostan reduces blood clots and Clanza relieves pain and inflammation.

(theinvestor@heraldcorp.com)

Korea United Pharm’s W38m contract canceled

More from Headlines